ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ブロムヘキシン

Bromhexine

HCID 2442
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
3572-43-8
標準SMILES
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
InChIKey
OJGDCBLYJGHCIH-UHFFFAOYSA-N
分子式
C14H20Br2N2
平均分子量
376.13 g/mol
単同位体質量
373.99932

概要

Bromhexine is a substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum). It has a role as a mucolytic. It is an organobromine compound, a substituted aniline and a tertiary amino compound. It is a conjugate base of a bromhexine(1+).

名称と識別子

優先名称
Bromhexine
IUPAC
2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline
現地名
ブロムヘキシン
英語名
Bromohexine
分子式
C14H20Br2N2
分子量
376.13

名称と別名

bromhexine3572-43-8Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-BromhexinaBromhexinumFluibron2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)anilineQ1J152VB1PCHEBI:770322,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}anilineDTXSID6022686
名称をさらに表示
N-シクロヘキシル-N-メチル-(2-アミノ-3,5-ジブロムベンジル)-アンモニウム塩ブロメキシン2-アミノ-3,5-ジブロモ-N-シクロヘキシル-N-メチルベンゼンメタンアミンブロムヘキシンアウキシト2,4-ジブロモ-6-{[シクロヘキシル(メチル)アミノ]メチル}アニリン6-[(N-メチルシクロヘキシルアミノ)メチル]-2,4-ジブロモアニリンBroMhexine IMpurity EBromexineAuxitNa 274Aids001646Aids-001646BromohexineAKOS B015997AURORA KA-7546
NA274N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamineBromexinaDurElixbromhexin von ctDur ElixBC, Bromhexin

物性

構造計算による物性

XLogP
4.3
極性表面積
29.3 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
3
重原子数
18
形式電荷
0
複雑度
256

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Solubility<1 mg/mL
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Expectorants

Pharmaceuticals

Melting Point232-235
Dissociation Constants8.69
Collision Cross Section167.85 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
238 ℃ · 238℃
沸点
413.8 · 413.8±40.0 °C(Predicted)
比重(密度)
1.57 · 1.57
貯蔵温度
2 · 2-8°C(protect from light)
溶解性
75 mg/mL · DMSO: 75 mg/mL (199.40 mM);Ethanol: 75 mg/mL (199.40 mM)
酸解離定数(Pka)
8.34 · 8.34±0.20(Predicted)
水溶解度
Water: Insoluble

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

P273, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 3 件

Chemical: Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-

REACH registered substance: Bromhexine (EC: 222-684-1)

Bromhexine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAquatic Acute 1 (100%)

毒性情報

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Bromhexine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

毒性
Approx LD50 orally in rabbits: >10 g/kg (Boyd, Sheppard)

化学と産業

薬理情報

ATC Code · 3 件

R05CB02

R - Respiratory system

QR - Respiratory system

Protein BindingBromhexine is approximately 95% bound to plasma proteins.
PharmacodynamicsBromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.
Mechanism of Action · 1 件

Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium, allowing secretions to be expelled from the respiratory tract. Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19. In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.

Biological Half-LifeFollowing single oral doses ranging from 8 and 32 mg, the terminal half-life of bromhexine has been measured between 6.6 and 31.4 hours.
Metabolism/Metabolites · 1 件

Bromhexine is almost completely metabolized to a variety of hydroxylated metabolites in addition to dibromanthranilic acid. Ambroxol is a known metabolite of bromhexine. In one study of human plasma, (E)-4-hydroxydemethylbromhexine (E-4-HDMB) and (E)-3-hydroxydemethylbromhexine (E-3-HDMB) were quantified as major metabolites of ambroxol, and (Z)-4-hydroxydemethylbromhexine and (Z)-3-hydroxydemethylbromhexine were quantified as minor metabolites.

関連反応

1 件
反応記録を作成
HRID 1506608 の反応式
HRID 1506608生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
3572-43-8
PubChem CID
2442
DTXSID
DTXSID6022686
ChEMBL
CHEMBL253376
ChEBI
CHEBI:77032
UNII
Q1J152VB1P
EC Number
222-684-1
Nikkaji
J8.165E
InChI
InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
InChIKey
OJGDCBLYJGHCIH-UHFFFAOYSA-N
SMILES
C1(CN(C2CCCCC2)C)=CC(Br)=CC(Br)=C1N
hs_code
2921590090
MeSH Pharmacological ClassificationAgents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Absorption, Distribution and Excretion · 4 件

After oral administration, bromhexine demonstrates linear pharmacokinetics when given in doses of 8-32 mg. Bromhexine is readily absorbed in the gastrointestinal tract at a rapid rate. This drug undergoes extensive first-pass effect in the range of 75-80%. The bioavailability is therefore reduced to approximately 22-27%.

After a dose of bromhexine was administered during a pharmacokinetic study, approximately 97% of the radiolabeled dose was detected in the urine; under 1% was detected as the parent drug.

After intravenous administration in a pharmacokinetic study, bromhexine was found to be widely distributed. Bromhexine is known to cross the blood-brain barrier; small concentrations may cross the placenta. The average volume of distribution of bromhexine was 1209 ± 206 L (19 L/kg). Lung tissue concentrations of bromhexine two hours after a dose were 1.5 to 3.2 times higher in bronchial tissues than plasma concentrations. Pulmonary parynchema concentrations were 3.4 to 5.9 times higher when compared to plasma concentrations.

The clearance of bromhexine ranges from 843-1073 mL/min, within the range of the hepatic circulation.

用途と製造

UsesUse (kg; approx.) in Germany (2009): >250
Use ClassificationPharmaceuticals

応用分野

使用Expectorant; mucolytic.

上流・下流製品情報

上流原料

2-ニトロベンジルブロミドヒドラジン (無水)N-メチルシクロヘキシルアミン
補足説明 · 1 件

定義ChEBI: A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive ough (i.e. a cough characterised by the production of sputum).